was geht denn hier ab...erstmal auf watch
bluebird bio to Present New Data from Three LentiGlobinTM Clinical Studies at American Society of Hematology (ASH) Annual Meeting
investor.bluebirdbio.com/...;p=irol-newsArticle&ID=2218784
Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2016 were $727.6 million, compared to $865.8 million as of December 31, 2015, a decrease of $138.2 million.
investor.bluebirdbio.com/...;p=irol-newsArticle&ID=2219192